 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

For the last three days, A.I.dvisor has detected that BLUE's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

bluebird bio (BLUE, $3.08) Aroon Indicator entered a Downtrend on September 26, 2023.

This is a signal that BLUE's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

bluebird bio (BLUE, $3.08) RSI Indicator left the oversold zone on September 26, 2023

bluebird bio (BLUE, $3.03) Aroon Indicator entered a Downtrend on September 25, 2023.

Investors eyeing a purchase of bluebird bio Inc (BLUE) shares, but cautious about paying the going market price of 3.15/share, might benefit from considering selling puts among the alternative...

Commit To Purchase bluebird bio At $1.50, Earn 20% Using Options

bluebird bio (BLUE, $3.04) RSI Indicator left the oversold zone on September 22, 2023

This price move could be a signal that BLUE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

bluebird bio (BLUE, $3.33) price may climb as it broke lower Bollinger Band on Sep 13, 2023

Gene editing is a relatively new technology that allows scientists to modify an organism's DNA. It holds the potential to help researchers develop therapies for diseases that have been extremely hard...

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

This is a Bearish indicator signaling BLUE's price could decline from here. Traders may explore shorting the stock or put options...

bluebird bio (BLUE, $3.57) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 8, 2023

Panagora Asset Management Inc. boosted its position in bluebird bio, Inc. (NASDAQ:BLUE  Free Report) by 35.5% during the first quarter, according to its most recent 13F filing with the SEC...

Panagora Asset Management Inc. Purchases 84,432 Shares of bluebird bio, Inc. (NASDAQ:BLUE)

Russell Investments Group Ltd. grew its position in shares of bluebird bio, Inc. (NASDAQ:BLUE  Free Report) by 53.2% in the first quarter, according to the company in its most recent 13F...

Russell Investments Group Ltd. Has $314,000 Stock Position in bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Watchers	5,703
52-Wk Low	$2.78
52-Wk High	$8.58

Market Cap	$327.28M
Volume (M)	1.98M
52-Wk High	$8.58
52-Wk Low	$2.78

BLUE Bluebird bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals